One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder
Katie Fitzgerald Jones, MSN; Dmitry Khodyakov, PhD; Robert Arnold, MD; et al.
doi : 10.1001/jamaoncol.2022.2191
August 2022, Vol 8, No. 8, Pages 1085-1227
Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity
Marissa B. Lawson, MD; Michael C. S. Bissell, PhD; Diana L. Miglioretti, PhD; et al.
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate CancerThe ENACT Randomized Clinical Trial
Neal D. Shore, MD; Joseph Renzulli, MD; Neil E. Fleshner, MD; et al.
Effect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of CancerA Randomized Clinical Trial
Manali I. Patel, MD, MPH, MS; Kristopher Kapphahn, MS; Marilyn Dewland, RN; et al.
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric AdenocarcinomaThe AIO INTEGA Randomized Clinical Trial
Alexander Stein, MD; Lisa Paschold, PhD; Joseph Tintelnot, MD; et al.
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti, MD; Xinan Wang, PhD; Joao V. Alessi, MD; et al.
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian CancerThe APPROVE Randomized Clinical Trial
Tiantian Wang, MD; Jie Tang, MD; Hongying Yang, MD; et al.
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
Paolo Tarantino, MD; Qingchun Jin, MPH; Nabihah Tayob, PhD; et al.
Trends in Cancer Mortality Among Black Individuals in the US From 1999 to 2019
Wayne R. Lawrence, DrPH; Jennifer K. McGee-Avila, PhD; Jacqueline B. Vo, PhD; et al.
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant ChemotherapyA Prespecified Analysis of the monarchE Randomized Clinical Trial
Miguel Martin, MD, PhD; Roberto Hegg, MD; Sung-Bae Kim, MD, PhD; et al.
Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer–Related Lymphedema
Giacomo Montagna, MD, MPH; Jennifer Zhang, MD; Varadan Sevilimedu, MBSS, DrPH; et al.
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults
Michelle Nadeau Nguyen, PharmD, BCOP, BCPS; Wiley Chambers, MD; Graça M. Dores, MD, MPH; et al.
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making
Bonnie O. Wong, MSc; Jacob A. Blythe, MD; Adela Wu, MD; et al.
Assessment of Compliance With Centers for Medicare & Medicaid Services Price Transparency Final Rule
Angelin Tresa Mathew, BS; Bhav Jain, BS; Edward Christopher Dee, MD; et al.
Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US
Koji Matsuo, MD, PhD; Maximilian Klar, MD, MPH; Ariane C. Youssefzadeh, MD; et al.
Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell CarcinomaSecondary Analysis of Keynote 048
Yao Yu, MD; Kaveh Zakeri, MD, MAS; Eric J. Sherman, MD; et al.
Demographic Patterns and Increasing Incidence of Cutaneous T-Cell Lymphoma in Louisiana
Jalal Maghfour, MD; Frances Gill, MD, MPH; Justin Olson, BS; et al.
Plant-Based and Ketogenic Diets As Diverging Paths to Address CancerA Review
Urvi A. Shah, MD; Neil M. Iyengar, MD
Maximizing Cancer Data—The Future of Cancer Is Now
Jill S. Barnholtz-Sloan, PhD
Inclusion and Reporting of Transgender and Nonbinary Persons in Clinical Trials and Tumor Registries—The Time Is Now
Chandler S. Cortina, MD, MS
Electronic Monitoring of Patient-Reported Outcomes—Ready for Prime Time?
Ana I. Velazquez, MD, MSc; Narjust Florez, MD
Short-term Health Insurance Plans Come Up Short for Patients With Cancer
Justin M. Barnes, MD, MS; Fumiko Chino, MD
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use
Joseph Arthur, MD; Eduardo Bruera, MD
Addressing Racial and Ethnic Differences in Diagnostic Resolution of Abnormal Mammographic Findings
Randy C. Miles, MD, MPH
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence
Susan Halabi, PhD; Bradley C. Carthon, MD, PhD; Wm Kevin Kelly, DO
Community Health Worker–Led Intervention Improves Acute Care Use and Advance Care Planning for Patients With Cancer
Ana I. Tergas, MD, MPH
AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma
Monica Patel, MD; Nataliya Uboha, MD, PhD
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In�?
Bruno Henrique Rala de Paula, MD, MSc; Susanne Crocamo, MD, PhD
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In�?—Reply
Paolo Tarantino, MD; Heather A. Parsons, MD, MPH; Sara M. Tolaney, MD, MPH
Prophylactic Antibiotic Regimens in Tumor Resection Surgery Involving a Prosthesis
Karin Veerman, MD; Heiman Wertheim, MD, PhD
Prophylactic Antibiotic Regimens in Tumor Resection Surgery Involving a Prosthesis—Reply
Michelle Ghert, MD; Patricia Schneider, BSc; Timothy O’Shea, MD, MPH
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma
Shuvadeep Ganguly, MD; Ajay Gogia, DM
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma
Nithin S. G., MD; Atul Sharma, MD, DM; Raja Pramanik, MD, DM
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma—Reply
Guo-Ying Liu, MD; Wang-Zhong Li, MD; Yan-Qun Xiang, MD
